Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Publications (10 of 81) Show all publications
Mickelsson, M., Ekblom, K., Stefansson, K., Liv, P., Nyman, E., Själander, A., . . . Hultdin, J. (2024). ABO blood groups, RhD factor and their association with subclinical atherosclerosis assessed by carotid ultrasonography. Journal of Clinical Medicine, 13(5), Article ID 1333.
Open this publication in new window or tab >>ABO blood groups, RhD factor and their association with subclinical atherosclerosis assessed by carotid ultrasonography
Show others...
2024 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 13, no 5, article id 1333Article in journal (Refereed) Published
Abstract [en]

Background: The ABO blood group system has previously been associated with cardiovascular disease (CVD), where non-O blood group individuals have shown an increased risk. Studies assessing early atherosclerotic disease while also including RhD are few. We aimed to determine whether the ABO and RhD blood groups are associated with subclinical atherosclerosis in a healthy population.

Methods: We included 3532 participants from the VIPVIZA trial with available carotid ultrasonography results to assess subclinical disease. Information about blood groups was obtained from the SCANDAT-3 database, where 85% of VIPVIZA participants were registered.

Results: RhD− individuals aged 40 years showed increased carotid intima–media thickness (B 1.09 CI 95% 1.03; 1.14) compared to RhD+ individuals. For ABO, there were no differences in ultrasonography results when assessing the whole study population. However, 60-year-old individuals with heredity for CVD and a non-O blood group had decreased odds for carotid plaques (OR 0.54 CI 95% 0.33; 0.88).

Conclusions: RhD blood group is associated with subclinical atherosclerosis in younger individuals, indicating a role as a mediator in the atherosclerotic process. In addition, a non-O blood group was associated with decreased subclinical atherosclerosis in individuals aged 60 and with heredity (corresponding to the group with the highest atherosclerotic burden).

Place, publisher, year, edition, pages
MDPI, 2024
Keywords
ABO blood group system, atherosclerosis, cardiovascular prevention, carotid intima–media thickness, carotid plaques, RhD factor
National Category
Cardiac and Cardiovascular Systems Hematology
Identifiers
urn:nbn:se:umu:diva-222584 (URN)10.3390/jcm13051333 (DOI)001182882700001 ()2-s2.0-85187443119 (Scopus ID)
Funder
Visare Norr, Dnr 981146Region Västerbotten, ALFVLL-298001Region Västerbotten, AALFVLL-643391Swedish Research Council, 521-2013-2708Swedish Research Council, 2016-01891Swedish Heart Lung Foundation, 20150369Swedish Heart Lung Foundation, 20170481
Available from: 2024-04-08 Created: 2024-04-08 Last updated: 2024-04-08Bibliographically approved
Holmberg, H., Glader, E.-L., Näslund, U., Carlberg, B., Sönnerstam, E., Norberg, M. & Själander, A. (2024). Improved adherence to statin treatment and differences in results between men and women after pictorial risk communication: a sub-study of the VIPVIZA RCT. European Journal of Clinical Pharmacology
Open this publication in new window or tab >>Improved adherence to statin treatment and differences in results between men and women after pictorial risk communication: a sub-study of the VIPVIZA RCT
Show others...
2024 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041Article in journal (Refereed) Epub ahead of print
Abstract [en]

Background: People with intermediate CVD risk constitute most of the population. Within this group, the proportion of events is lower compared to the high-risk group, but they contribute with the largest absolute number of events. Atherosclerosis is a dynamic process and progression can be slowed or even reversed with medication and lifestyle changes, but adherence to prescribed treatment is crucial.

Aim: To investigate the long-term effects of interventions with pictorial risk communication of cardiovascular (CVD) risk on average adherence in a group of statin users. Compare response in adherence over time between men and women after intervention.

Methods: Participants on active statin treatment were followed up to 5 years after being randomly assigned to an intervention program aimed at raising CVD risk awareness among participants and their physicians. Merging prescribed medication databases with VIPVIZA study to study adherence over time. A moving average adherence was used to compare groups.

Results: Generally, the average adherence to statins among the 512 participants was high. Men had a higher average adherence over time, while women had a sharper increase in adherence in conjuncture with the intervention program.

Conclusions: Both men and women were receptive to pictorial information regarding CVD risk, but the intervention effect was more pronounced in women. Sex differences are important when considering risk communication strategies. Periodically repeating the intervention was beneficial for maintaining the intervention effect over time.

Trial registration: The VIPVIZA study is registered with ClinicalTrials.gov, May 8, 2013, number NCT01849575.

Place, publisher, year, edition, pages
Springer, 2024
Keywords
Atherosclerosis, Cardiovascular disease prevention, Cardiovascular risk, Pictorial information, Statin initiation, Statins
National Category
Public Health, Global Health, Social Medicine and Epidemiology Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-224129 (URN)10.1007/s00228-024-03694-6 (DOI)001209527900001 ()38684558 (PubMedID)2-s2.0-85191700644 (Scopus ID)
Funder
Region Västerbotten, ALFVLL-298001Region Västerbotten, ALFVLL-643391Swedish Research Council, 521-2013-2708Swedish Research Council, 2016-01891Swedish Heart Lung Foundation, 20150369Swedish Heart Lung Foundation, 20170481Swedish Society of MedicineNorrländska HjärtfondenThe Swedish Stroke AssociationSwedish Social Insurance AgencyVisare NorrThe Swedish Heart and Lung Association
Available from: 2024-05-14 Created: 2024-05-14 Last updated: 2024-05-14
Lilja, J., Själander, A. & Själander, S. (2024). Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants. Journal of Thrombosis and Thrombolysis, 57, 101-106
Open this publication in new window or tab >>Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
2024 (English)In: Journal of Thrombosis and Thrombolysis, ISSN 0929-5305, E-ISSN 1573-742X, Vol. 57, p. 101-106Article in journal (Refereed) Published
Abstract [en]

Objectives: To investigate the prevalence of atrial fibrillation (AF), the proportion of AF patients not receiving oral anticoagulation (OAC) and reasons for abstaining from OAC treatment.

Methods: A retrospective cross-sectional study of patients aged 18 years or older with an AF diagnosis on June 1st 2020 in Västernorrland County, Sweden. AF diagnosis was retrieved using the ICD10 code I.48, and medical records were reviewed for comorbidities and documented reasons to abstain OAC treatment.

Results: Of 197 274 residents in Västernorrland County, 4.7% (9 304/197 274) had a documented AF diagnosis. Of these, 19% (1 768/9 304) had no OAC treatment, including 4.2% (393/9 304) with no indication, 2.5% (233/9 304) with a questionable and 2.5% (231/9 304) with a documented clear contraindication for OAC. In total 9.8% (911/9 304) were not treated with OAC despite indication and no reasonable documented contraindication, thus 90.8% (8 447/9 304) of all AF-patients were eligible for OAC treatment. Common reasons for abstaining treatment without reasonable contraindication were present sinus rhythm in 13.7% (125/911), perceived not an OAC candidate in 10.6% (97/911) and anemia in the past in 4.3% (39/911).

Conclusions: In the population of Västernorrland County, a very high AF prevalence of 4.7% was found, of which just over 90% would theoretically benefit from OAC treatment. This is higher than previously reported and stresses the importance of stroke prevention in this large patient group.

Place, publisher, year, edition, pages
Springer Nature, 2024
Keywords
Atrial fibrillation, Oral anticoagulation, Prevalence
National Category
Cardiac and Cardiovascular Systems Public Health, Global Health, Social Medicine and Epidemiology
Identifiers
urn:nbn:se:umu:diva-214615 (URN)10.1007/s11239-023-02890-y (DOI)001066559300001 ()37704908 (PubMedID)2-s2.0-85171163870 (Scopus ID)
Available from: 2023-09-27 Created: 2023-09-27 Last updated: 2024-04-26Bibliographically approved
Enblom-Larsson, A., Renlund, H., Andréasson, B., Holmberg, H., Liljeholm, M. & Själander, A. (2024). Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera: a matched nationwide population-based study. British Journal of Haematology
Open this publication in new window or tab >>Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera: a matched nationwide population-based study
Show others...
2024 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141Article in journal (Refereed) Epub ahead of print
Abstract [en]

Thromboembolic events and bleeding are known complications in essential thrombocythaemia (ET) and polycythaemia vera (PV). Using multiple Swedish health care registers, we assessed the rate of arterial and venous events, major bleeding, all-cause stroke and all-cause mortality in ET and PV compared to matched controls. For each patient with ET (n = 3141) and PV (n = 2604), five matched controls were randomly selected. In total, 327 and 405 arterial or venous events were seen in the group of ET and PV patients respectively. Compared to corresponding controls, the rate of venous thromboembolism, major bleeding and all-cause mortality per 100 treatment years was significantly increased among both ET (0.63, 0.79 and 3.70) and PV patients (0.94, 1.20 and 4.80). The PV patients also displayed a significantly higher rate of arterial events and all-cause stroke compared to controls. When dividing the cohort into age groups, we found a significantly higher rate of arterial and venous events in all age groups of PV patients, and the rate of all-cause mortality was significantly higher in both ET and PV patients in all ages above the age of 50. This study confirms that PV and ET are diseases truly marked by thromboembolic complications and bleeding.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
essential thrombocythaemia, polycythaemia vera, thrombosis (venous), thrombosis - arterial
National Category
Hematology Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-221663 (URN)10.1111/bjh.19337 (DOI)38351734 (PubMedID)2-s2.0-85185487280 (Scopus ID)
Funder
The Swedish Stroke AssociationVisare Norr
Available from: 2024-03-04 Created: 2024-03-04 Last updated: 2024-03-04
Hayat, A., Själander, A. & Wallvik, J. (2023). Direct oral anticoagulants: patient reported adherence and minor bleedings. Journal of Thrombosis and Thrombolysis, 56(1), 55-64
Open this publication in new window or tab >>Direct oral anticoagulants: patient reported adherence and minor bleedings
2023 (English)In: Journal of Thrombosis and Thrombolysis, ISSN 0929-5305, E-ISSN 1573-742X, Vol. 56, no 1, p. 55-64Article in journal (Refereed) Published
Abstract [en]

Data regarding adherence and minor bleeding on direct oral anticoagulants in everyday life are still sparse. Inclusion criteria: treatment initiated with dabigatran, rivaroxaban or apixaban in non-valvular atrial fibrillation patients from a center in northern Sweden between 2011 and 2019 (n = 668). Exclusion criteria: cognitive impairment, dose dispensing, need of interpreter or hospital admission (n = 67). By a telephone interview adherence was measured in 569 patients (response rate 94.8%) using the 8-item Morisky medication adherence scale and minor bleeding was asked for. CHA2DS2-VASc and HAS-BLED scores were collected from medical records. The number (n), mean age, mean treatment duration, mean (points) CHA2DS2-VASc and HAS-BLED scores was with dabigatran (n = 175, 73.3 years, 17.8 months, 3.6 p and 2.2 p), rivaroxaban (n = 198, 73.7 years, 21months, 3.8 p and 2.1 p) and apixaban (n = 196, 72.7 years, 15.2 months, 3.4 p and 2.1 p). Adherence was high for dabigatran, rivaroxaban and apixaban in 54%, 76% and 53%; intermediate in 37%, 20% and 37% or low in 9%, 4% and 10% respectively. High adherence (Morisky score 8) distinguished rivaroxaban (p < 0.0001) and in patients with CHA2DS2-VASc ≥ 4 p, (p < 0.0001). Patients on rivaroxaban/apixaban reported more minor bleedings (37% / 28%) compared to dabigatran (13%), (p < 0.001). Only 61% of the patients followed prescription. Adherence to rivaroxaban was significantly better, maybe due to the once daily dosing regimen, and furthermore among patients with higher risk for stroke. Minor bleedings were less common in the dabigatran group. The impact of minor bleedings on adherence and a possible relationship to clinical outcomes need to be further studied.

Place, publisher, year, edition, pages
Springer, 2023
Keywords
8-item Morisky medication adherence scale, Adherence, Atrial fibrillation, Direct oral anticoagulants, Minor bleedings, Real world
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-208225 (URN)10.1007/s11239-023-02797-8 (DOI)000976121900001 ()37119356 (PubMedID)2-s2.0-85153928648 (Scopus ID)
Funder
Umeå University
Available from: 2023-05-12 Created: 2023-05-12 Last updated: 2023-09-20Bibliographically approved
Welander, F., Renlund, H., Dimény, E., Holmberg, H. & Själander, A. (2023). Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D. Clinical Kidney Journal, 16(5), 835-844
Open this publication in new window or tab >>Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D
Show others...
2023 (English)In: Clinical Kidney Journal, ISSN 2048-8505, E-ISSN 2048-8513, Vol. 16, no 5, p. 835-844Article in journal (Refereed) Published
Abstract [en]

Background: The use of direct oral anticoagulants (DOAC) in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD) including dialysis is growing. Several studies have shown favorable results of DOAC compared with warfarin regarding bleeding risk but no difference in stroke protection. However, these studies had poor time in therapeutic range (TTR), in the warfarin comparison group.

Methods: This was a Swedish national cohort study investigating the risk of ischemic stroke and major bleeding on DOAC compared with warfarin in patients with NVAF, glomerular filtration rate category 3-5D (G3-G5D), kidney transplant recipients excluded, between 2009 and 2018. Data extracted from high-quality national healthcare registries including the Swedish Renal Registry, AuriculA (the Swedish national quality register for AF and anticoagulation) and The Stroke Register.

Results: At enrolment, of 2453 patients 59% were treated with warfarin (mean TTR 67%) and 41% with DOAC. Overall, 693 (28.3%) had G3, 1113 (45.4%) G4, 222 (9.1%) G5 and 425 (17.3%) G5D. DOAC compared with warfarin showed lower hazard of major bleeding [hazard ratio 0.71 (95% confidence interval 0.53-0.96)] but no difference in ischemic stroke risk. Mortality was increased during DOAC treatment [1.24 (1.01-1.53)], presumably not a causal association since fewer fatal bleedings occurred on DOAC.

Conclusions: DOAC treatment, compared with warfarin, is associated with almost 30% lower risk of bleeding in patients with NVAF and CKD G3-G5D. The stroke risk is comparable between the treatments. This is the first study comparing DOAC and well-managed warfarin (TTR 67%) in advanced CKD. Ongoing and planned randomized controlled trials need to confirm the possible benefit of DOAC.

Place, publisher, year, edition, pages
Oxford University Press, 2023
Keywords
anticoagulants, atrial fibrillation, chronic kidney disease, dialysis
National Category
Cardiac and Cardiovascular Systems Urology and Nephrology
Identifiers
urn:nbn:se:umu:diva-214743 (URN)10.1093/ckj/sfad004 (DOI)000942734700001 ()37151425 (PubMedID)2-s2.0-85171785255 (Scopus ID)
Funder
Region Västernorrland, LVNFOU938547The Swedish Stroke AssociationThe Swedish Kidney Foundation, F2022-0084The Swedish Kidney Foundation, F2021-0105Swedish Heart Lung Foundation, 20200766
Available from: 2023-10-02 Created: 2023-10-02 Last updated: 2023-11-05Bibliographically approved
Gummesson, C., Alm, S., Cederborg, A., Ekstedt, M., Hellman, J., Hjelmqvist, H., . . . Tejera, A. (2023). Entrustable professional activities (EPAs) for undergraduate medical education: development and exploration of social validity. BMC Medical Education, 23(1), Article ID 635.
Open this publication in new window or tab >>Entrustable professional activities (EPAs) for undergraduate medical education: development and exploration of social validity
Show others...
2023 (English)In: BMC Medical Education, E-ISSN 1472-6920, Vol. 23, no 1, article id 635Article in journal (Refereed) Published
Abstract [en]

Background: The development of entrustable professional activities (EPAs) as a framework for work-based training and assessment in undergraduate medical education has become popular. EPAs are defined as units of a professional activity requiring adequate knowledge, skills, and attitudes, with a recognized output of professional labor, independently executable within a time frame, observable and measurable in its process and outcome, and reflecting one or more competencies. Before a new framework is implemented in a specific context, it is valuable to explore social validity, that is, the acceptability by relevant stakeholders.

Aim: The aim of our work was to define Core EPAs for undergraduate medical education and further explore the social validity of the constructs.

Method and material: In a nationwide collaboration, EPAs were developed using a modified Delphi procedure and validated according to EQual by a group consisting of teachers nominated from each of the seven Swedish medical schools, two student representatives, and an educational developer (n = 16). In the next step, social validity was explored in a nationwide survey. The survey introduced the suggested EPAs. For each EPA, the importance of the EPA was rated, as was the rater’s perception of the present graduates’ required level of supervision when performing the activity. Free-text comments were also included and analyzed.

Results: Ten Core EPAs were defined and validated. The validation scores for EQual ranged from 4.1 to 4.9. The nationwide survey had 473 responders. All activities were rated as “important” by most responders, ranging from 54 to 96%. When asked how independent current graduates were in performing the ten activities, 6 to 35% reported “independent”. The three themes of the free text comments were: ‘relevant target areas and content’; ‘definition of the activities’; and ‘clinical practice and learning’.

Conclusion: Ten Core EPAs were defined and assessed as relevant for Swedish undergraduate medical education. There was a consistent gap between the perceived importance and the certainty that the students could perform these professional activities independently at the time of graduation. These results indicate that the ten EPAs may have a role in undergraduate education by creating clarity for all stakeholders.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2023
Keywords
Entrustable professional activities, Development, Social validity
National Category
Clinical Medicine Other Medical Sciences not elsewhere specified Educational Sciences
Identifiers
urn:nbn:se:umu:diva-214135 (URN)10.1186/s12909-023-04621-6 (DOI)37667366 (PubMedID)2-s2.0-85169664954 (Scopus ID)
Funder
Malmö University
Available from: 2023-09-05 Created: 2023-09-05 Last updated: 2024-04-11Bibliographically approved
Enblom, A., Andréasson, B., Holmberg, H., Liljeholm, M. & Själander, A. (2023). Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event: a population based cohort study. European Journal of Haematology, 110(6), 608-617
Open this publication in new window or tab >>Erythrocytosis, thrombocytosis, and rate of recurrent thromboembolic event: a population based cohort study
Show others...
2023 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 110, no 6, p. 608-617Article in journal (Refereed) Published
Abstract [en]

Introduction: The management to reduce risk of thromboembolic complications in polycythemia vera and essential thrombocythemia are well established, but for other conditions with elevated hemoglobin, hematocrit, or platelets there are no consensus regarding treatment and follow up.

Aims: To assess frequency of elevated blood values in patients with thromboembolic event, how many of these should be investigated further regarding myeloproliferative neoplasm and if the risk of recurrent event is depending on underlying condition.

Methods: Retrospective cohort study of 3931 adult patients in the county of Norrbotten, Sweden, with thromboembolism during 2017 and 2018.

Results: Of the 3931 patients, 1195 had either elevated Hb, HCT, or platelets fulfilling the 2016 revised WHO criteria for PV and ET, and out of these 411 should be evaluated regarding underlying myeloproliferative neoplasms. Unexplained thrombocytosis and secondary erythrocytosis were associated with the highest rate of recurrent event as well as the most inferior restricted mean survival time.

Conclusion: Elevated blood values are common in patients with thromboembolic event and the high risk of recurrent event and inferior restricted mean survival time in patients with unexplained thrombocytosis and secondary erythrocytosis implicates the importance of finding and managing the underlying condition.

Place, publisher, year, edition, pages
John Wiley & Sons, 2023
Keywords
essential thrombocythemia, polycythemia, polycythemia vera, thrombocytosis, thromboembolism
National Category
Hematology
Identifiers
urn:nbn:se:umu:diva-205189 (URN)10.1111/ejh.13938 (DOI)000932888700001 ()36725666 (PubMedID)2-s2.0-85147986248 (Scopus ID)
Funder
Norrbotten County Council
Available from: 2023-02-28 Created: 2023-02-28 Last updated: 2023-07-12Bibliographically approved
Jansson, M., Själander, S., Sjögren, V., Björck, F., Renlund, H., Norrving, B. & Själander, A. (2023). Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 55(3), 415-425
Open this publication in new window or tab >>Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
Show others...
2023 (English)In: Journal of Thrombosis and Thrombolysis, ISSN 0929-5305, E-ISSN 1573-742X, Vol. 55, no 3, p. 415-425Article in journal (Refereed) Published
Abstract [en]

Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are dose-reduced in elderly and patients with impaired renal function. Only reduced dose dabigatran is concluded as having similar stroke risk reduction and lower risk of major bleeding than warfarin in the pivotal studies. In clinical practice, reduced dose is prescribed more often than expected making this an important issue. The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The median durations of follow up were 365, 419, 432 and 473 days for apixaban, dabigatran, rivaroxaban and warfarin, respectively. Warfarin TTR identified from Auricula was 70.0%. Endpoints (stroke and major bleeding) and baseline characteristics were collected from hospital administrative registers using ICD-10 codes. Cohorts were compared using weighted adjusted Cox regression after full optimal matching based on propensity scores. DOACs are associated with lower risk of major bleeding (HR with 95% CI) 0.85 (0.78–0.93), intracranial bleeding HR 0.64 (0.51–0.80), hemorrhagic stroke HR 0.68 (0.50–0.92), gastrointestinal bleeding HR 0.81 (0.69–0.96) and all-cause stroke HR 0.87 (0.76–0.99), than warfarin. Apixaban and dabigatran are associated with lower risk of major bleeding, HR 0.70 (0.63–0.78) and HR 0.80 (0.69–0.94), and rivaroxaban is associated with lower risk of ischemic stroke, HR 0.73 (0.59–0.96), with higher major bleeding risk, HR 1.31 (1.15–1.48), compared to warfarin. Apixaban is associated with higher all-cause mortality compared to warfarin, HR 1.12 (1.03–1.21). DOACs are associated with lower risk of major bleeding and all-cause stroke, than high quality warfarin treatment, with exception of rivaroxaban that carried higher risk of major bleeding and lower risk of stroke or systemic embolism. In this large observational registry-based NVAF cohort, DOACs are preferred treatment in patients with indication for DOAC dose reduction, even in a high TTR setting.

Place, publisher, year, edition, pages
Springer Nature, 2023
Keywords
Anticoagulants, Apixaban, Atrial fibrillation, Dabigatran, Rivaroxaban, Treatment outcome, Warfarin
National Category
Cardiac and Cardiovascular Systems
Identifiers
urn:nbn:se:umu:diva-203564 (URN)10.1007/s11239-022-02763-w (DOI)000909142700001 ()36607464 (PubMedID)2-s2.0-85145851437 (Scopus ID)
Funder
Swedish Heart Lung Foundation, 20200766
Available from: 2023-01-19 Created: 2023-01-19 Last updated: 2023-09-21Bibliographically approved
Dahlén, T., Flygt, H., Lübking, A., Olsson-Strömberg, U., Wennström, L., Dreimane, A., . . . Nyberg, F. (2023). The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study [Letter to the editor]. Leukemia, 37, 1156-1159
Open this publication in new window or tab >>The impact of Covid-19 in patients with chronic myeloid leukemia: a nationwide population-based study
Show others...
2023 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 37, p. 1156-1159Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
Springer Nature, 2023
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-206932 (URN)10.1038/s41375-023-01893-1 (DOI)000966673500001 ()37037908 (PubMedID)2-s2.0-85152379480 (Scopus ID)
Available from: 2023-04-28 Created: 2023-04-28 Last updated: 2023-07-14Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0001-9422-1186

Search in DiVA

Show all publications